Incannex Healthcare Inc.IXHLEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical firm developing proprietary cannabinoid and psychedelic-derived therapies for unmet medical needs in respiratory, neurological, and inflammatory disorder segments. It advances its pipeline via global clinical trials to secure regulatory approvals for commercialization.
IXHL Q3 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-5.0M
Net Profit
$-4.0M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.20
Incannex Healthcare Inc. Q3 FY2025 Financial Summary
Incannex Healthcare Inc. reported revenue of $0 for Q3 FY2025, with a net profit of $-4.0M (up 34.2% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-4.0M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2025 |
Incannex Healthcare Inc. Quarterly Revenue & Net Profit History
Incannex Healthcare Inc. results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $0 | — | $-4.0M | N/A |
| Q2 FY2025 | $12.0K | — | $-5.9M | -49116.7% |
| Q1 FY2025 | $74.0K | — | $-5.4M | -7324.3% |
Income Statement
| Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|
| Revenue | $74000 | $12000 | $0 |
| YoY Growth | N/A | N/A | N/A |
Balance Sheet
| Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|
| Assets | $16.0M | $11.1M | $16.2M |
| Liabilities | $9.5M | $10.1M | $8.8M |
| Equity | $6.6M | $964000 | $7.4M |
Cash Flow
| Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|
| Operating CF | $-2.2M | $-5.6M | $-3.2M |